10x Genomics (NASDAQ: TXG) reported Q1 EPS of ($0.38), $0.07 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $114.5 million versus the consensus estimate of $113.34 million.

GUIDANCE:

10x Genomics sees FY2022 revenue of $600-630 million, versus the consensus of $614 million.

For earnings history and earnings-related data on 10x Genomics (TXG) click here.